AcuityMD Company Spotlight: MedTech's Intelligence Layer

AcuityMD is building the commercial intelligence layer for an industry that can map the anatomy of a device in extraordinary detail while still sending sales teams into the market with fragmented data. Founded in Boston in 2019, the company combines healthcare-market data, each customer's operating context, and purpose-built workflow software to help MedTech teams decide where to compete and how to reach the right physicians.

The platform now serves more than 500 MedTech companies, according to AcuityMD, including 16 of the top 20. Its product suite stretches from market sizing and territory design through targeting, pipeline, care journeys, contracts, forecasting, and AI-assisted execution. That breadth makes AcuityMD more than a data vendor and gives the company a clear place in the next phase of vertical AI.

CEO Michael Monovoukas, CTO Robert Coe, and VP of Customer Experience Lee Smith founded AcuityMD around a commercial problem they understood from inside the industry. The company has since raised more than $160M, reached a reported $955M valuation, and built a hiring pipeline around the engineering and product work required to turn MedTech context into everyday decisions.

About AcuityMD

AcuityMD sells intelligence software to companies bringing medical devices and related technologies to market. Its customers range from pre-commercial startups to global manufacturers, including Becton Dickinson, Olympus, and Teleflex. The company's mission is to accelerate adoption of medical technology by helping commercial teams understand where care happens, which physicians and facilities matter, how markets are changing, and where a product has room to grow.

That mission sits in the uncomfortable gap between regulatory approval and patient access. A device can clear years of scientific, clinical, and regulatory work and still struggle commercially because the team cannot see the right account, referral network, procedure trend, reimbursement change, or contracting opportunity. AcuityMD makes that market legible enough for sales, marketing, commercial operations, and leadership to coordinate around it.

The Platform Behind the Company

The AcuityMD platform is organized around the commercial lifecycle. Markets helps teams size and segment opportunities. Territories aligns sales coverage with physician, facility, and geographic data. Targeting surfaces high-value providers and sites of care. Pipeline tracks opportunities through the sales process, while Contracts identifies on-contract whitespace and Care Journeys maps patient and referral movement. Forecasting and CRM integrations connect those views to execution.

The common layer is data. AcuityMD says its all-payer claims dataset represents more than 330M patients and is refreshed alongside information from other data partners. The company combines that market record with each customer's territory definitions, pricing, sales history, product strategy, and CRM activity.

AcuityAI adds an agentic interface to that system. It can help a rep build target lists, plan a route, prepare for a physician conversation, draft follow-up, and identify next actions. The distinction is not that AcuityMD has access to language models. It is that the model can work inside a MedTech ontology and customer-specific commercial context that a general prompt does not contain.

Leadership and Founding Logic

Michael Monovoukas, Robert Coe, and Lee Smith founded AcuityMD in 2019. Monovoukas had previously built in MedTech, held a leadership role at PatientPing, and advised life-sciences companies at Bain. Smith brought direct commercial experience from larger MedTech organizations, while Coe supplied the technical foundation required to turn fragmented industry data into a software platform.

That combination shaped the company's product direction. AcuityMD started with targeting and market visibility, then expanded into the connected workflows surrounding a MedTech sale. Current leaders include Adam Berger in engineering, Rob Bergland in finance and business operations, Brittany Macaulay in marketing, Alex Wakefield in revenue, and Brian Collins in product.

Traction and Market Position

AcuityMD says more than 500 companies use the platform and that customers have identified more than $34B in pipeline. Its customer base includes large manufacturers and growth-stage device companies, giving the platform exposure to product launches, territory design, referral pathways, contract performance, and market expansion across different specialties.

The company reported 1,061% revenue growth from 2022 through 2025 when it announced a No. 316 ranking on the 2026 Inc. 5000. It also ranked No. 28 among software companies on that list. Those figures are reported by AcuityMD, but the operating progression is visible: the company crossed 200 customers in 2024, 300 in early 2025, and 500 in July 2026.

Capital has followed that expansion. AcuityMD's $80M Series C, led by StepStone Group, brought total funding above $160M in April 2026. The company said the round would accelerate agentic AI, deepen its MedTech ontology, and expand the platform beyond commercial teams across the product lifecycle.

Culture and Hiring as a Market Signal

AcuityMD's careers page describes a remote-first company with a Boston home base and a team distributed across the U.S. and Canada. Its stated values are simplify and innovate, be a compounding force, build with grit, learn with empathy, and practice constructive transparency. The company says employees receive equity, development stipends, mentorship, career pathing, health coverage, PTO, mental-health resources, and parental leave.

The hiring signal matters because AcuityMD's next product phase is technically and commercially broader than the last one. A current investor job board showed 10 open roles, including application engineering. Building agents that act across territory planning, account strategy, CRM updates, forecasting, and eventually the full product lifecycle requires more than model access. It requires people who can translate MedTech operating reality into dependable software and data systems.

Why AcuityMD Matters Now

Vertical AI companies are being forced to answer a harder question than whether a model can generate useful text. They must prove they own enough context, workflow, and customer trust to influence decisions. AcuityMD has spent years assembling those ingredients in a market where the difference between an interesting lead and a commercial opportunity can sit inside one procedure code, physician relationship, contract, or reimbursement change.

The company's durable advantage will depend on how well that context survives expansion. Commercial targeting, portfolio strategy, product development, reimbursement, and launch planning share information, but they do not share identical definitions of risk or success. AcuityMD has earned a place inside the commercial system. Its next chapter is the attempt to make that system useful across more of the MedTech company without sanding away the distinctions that made the data valuable in the first place.